Paraoxonase 1 (PON1) activity and metabolic syndrome traits were evaluated in 169 demented patients (81 recognized as AD, 32 as VaD, 56 as MD) and in 64 control individuals. Paraoxonase activity was determined spectrophotometrically using phenyloacetate as substrate. Metabolic syndrome was recognized according to AHA/NHLBI criteria.
In the whole group with dementia significant positive correlation between PON1 activity/HDL cholesterol ratio (i.e. HDL corrected PON1 activity) and insulin level as well as HOMA IR index, was observed. The multivariate analysis showed that the PON1/HDL-C ratio was also significantly positively associated with the presence of metabolic syndrome (with insulin resistance as a major underlying trait) both in dementia and in control group. High insulin level and HOMA-IR are considered to be the traits of insulin resistance. It has however to be taken into account that they both could also depend on insulin production and release which, as was recently stated in cell experiments, are enhanced by PON1. The observed positive correlation suggests an advantageous role of the enzyme in metabolic syndrome influence on dementia development.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Macness MI: Human serum paraoxonase.Gen Pharmacol. 1998; 31: 1: 329-336
- High-density lipoprotein composition and paraoxonase activity in type I diabetes.Clin Sci. 2001; 101: 659-670
- Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups.Atherosclerosis. 2006; 185: 191-200
- Promoter polymorphism of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations.Arterioscler Thromb Vasc Biol. 2000; 20: 516-521
- Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.Am J Hum Genet. 1993; 52: 598-608
- The human serum paraoxonase/arylesterase polymorphism.Am J Hum Genet. 1983; 35: 1126-1138
- Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases.Free Radic Biol Med. 2004; 37: 1301
- Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.Eur Arch Psychiatry Clin Neurosci. 2002; 252: 63-67
- Paraoxonase 1 activity: a new vascular marker of dementia?.Ann N Y Acad Sci. 2002; 977: 96-101
- Paraoxonase activity and dementia.J Neurol Sci. 2009; 283: 105-109
- Antioxidant paraoxonase activity in the metabolic syndrome.J Clin Endocrinol Metab. 2003; 88: 5422-5426
- Italian Longitudinal Study on Ageing Working Group. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing.J Neurol Neurosurg Psychiatry. 2010; 81: 433-440
- Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population.Metabolism. 2001; 50: 805-811
- Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations and appropriate usage.Am J Physiol Metab. 2008; 294: E15-E26
- Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary.Circulation. 2005; 112: e285-e290
- Definition, diagnosis and classification of diabetes mellitus and its complications.Report of a WHO consultation. World Health Organization, Geneva1999
- Effect of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase.Biochem J. 1973; 135: 93-99
- Effects of 5' regulatory-region polymorphism on paraoxonase gene (PON1) expression.Am J Hum Genet. 2001; 68: 1428-1436
- The molecular basis of the human serum paraoxonase activity polymorphism.Nat Genet. 1993; 3: 73-76
- Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients.Kidney Int. 1999; 56: 289-298
- Lower serum paraoxonase-1 activity is related to linoleic and docosahexanoic fatty acids in patients with type 2 diabetes.Arch Med Res. 2012; 43: 75-82
- Evaluation of insulin sensitivity in clinical practice and in research settings.Nutr Rev. 2003; 61: 397-412
- Diabetes Care. 2011; 34: 562-568
- The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release.Atherosclerosis. 2011; 219: 510-518
- Association of paraoxonase 1 polymorphism with beta-cell function: a case of molecular heterosis.Pancreas. 2004; 28: e96-e103
Published online: November 26, 2012
Accepted: November 1, 2012
Received: April 27, 2012
© 2012 Elsevier B.V. Published by Elsevier Inc. All rights reserved.